Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + TH-302 vs Gemcitabine + Placebo in Unresectable or Metastatic Pancreatic Adenocarcinoma
2012-002957-42Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing Gemcitabine + TH-302 with Gemcitabine + Placebo (2 arms). Primary endpoint: Overall survival. Started Apr 2013; status: completed.
02
Drugs
evofosfamide
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2012-002957-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002957-42.